| Theme | Autoimmune Pancreatitis -- Present Status & Future Perspectives | |
|---|---|---|
| Title | Long—term Outcome and Management of Autoimmune Pancreatitis | |
| Publish Date | 2018/02 | |
| Author | Kenji Hirano | Department of Gastroenterology, Tokyo Takanawa Hospital / Department of Gastroenterology, The University of Tokyo Graduate School of Medicine |
| Author | Takeo Watanabe | Department of Gastroenterology, Tokyo Takanawa Hospital |
| Author | Hisato Maekawa | Department of Gastroenterology, Tokyo Takanawa Hospital |
| Author | Tomoka Nakamura | Department of Gastroenterology, The University of Tokyo Graduate School of Medicine |
| Author | Yosuke Nakai | Department of Gastroenterology, The University of Tokyo Graduate School of Medicine |
| Author | Kazuhiko Koike | Department of Gastroenterology, The University of Tokyo Graduate School of Medicine |
| [ Summary ] | Although spontaneous remission of autoimmune pancreatitis (AIP) is sometimes observed, corticosteroid treatment (CST) is necessary in principle in light of high relapse rate of untreated AIP. It is known that maintenance CST is useful for preventing relapses. The Japanese AIP guideline proposes 3‒year maintenance therapy, but 3 years is not probably adequate because of the high relapse rate after the cessation of CST. Considering steroid side effects, it is difficult to decide the duration of CST. It is unclear whether the risk of malignancy in AIP is high or not. The risk of malignancy might be slightly high, but with no serious impact requiring a drastic revision of the long‒term management of AIP. | |